David Cicilline actually said...

Product hopping causes patients to overpay by potentially billions of dollars annually for their prescription drugs.

I think that regulatory reform and competition advocacy are very, very important.

You can't just do that and expect these healthcare pharma issues to be taken care of without funding those agencies.

We need to get that done immediately. That will add significant resources to the two agencies, plus the appropriations policy.